Miller Tonya L K, Park Raymond, Sun Lena S
*Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School†Division of Pediatric Anesthesia, Department of Anesthesiology, Columbia University Medical Center, New York, NY.
J Neurosurg Anesthesiol. 2016 Oct;28(4):350-355. doi: 10.1097/ANA.0000000000000346.
On April 16 and 17, 2016, the Pediatric Anesthesia and Neurodevelopment Assessment (PANDA) study held its fifth biennial symposium at the Morgan Stanley Children's Hospital of New York. The PANDA symposium has served as a key forum for clinicians, researchers, and other major stakeholders to gather and review the current state of preclinical and clinical research related to anesthetic neurotoxicity in children. Goals of the meeting included assessing how current knowledge has translated and impacted clinical care of patients who may be at risk, and future directions for research and policy. The program participants represented a diverse group with a shared concern of potential anesthetic neurotoxicity in children. It included clinicians, preclinical and clinical researchers as well as representatives from government organizations (FDA [Food and Drug Administration] and National Institutes of Health). A total of 135 attended the symposium.
2016年4月16日和17日，儿科麻醉与神经发育评估（PANDA）研究在纽约摩根士丹利儿童医院举办了第五届两年一度的研讨会。PANDA研讨会一直是临床医生、研究人员及其他主要利益相关者齐聚一堂，审视儿童麻醉神经毒性相关临床前和临床研究现状的关键论坛。会议目标包括评估现有知识如何转化并影响可能面临风险的患者的临床护理，以及研究和政策的未来方向。参会人员构成多样，他们都对儿童潜在的麻醉神经毒性表示关切。其中包括临床医生、临床前和临床研究人员以及政府组织（美国食品药品监督管理局[FDA]和美国国立卫生研究院）的代表。共有135人参加了此次研讨会。
